Ultraman increases longevity technology: Retro Biosciences wants to raise US$1 billion to challenge the limit of human lifespan

Retro Biosciences, a biotech startup backed by OpenAI CEO Sam Altman, is raising a $1 billion Series A round of financing to further increase its ambition to extend human lifespan. Altman previously invested $180 million in seed round financing into the company. The goal of Retro Biosciences is not only to extend human lifespan, but also to extend healthy lifespan so that people can remain healthy at the end of life.

The San Francisco-based startup plans to use AI technology to accelerate drug development and has launched a new drug targeting Alzheimer's disease. Drug trials for diseases such as Alzheimer's. According to reports, Retro Biosciences recently used OpenAI to train a model that can transform ordinary cells into stem cells. The company's CEO, Joe Bates-Lacroix, said he hopes to quickly discover and develop a drug to extend human lifespan in the 2020s.

Retro Biosciences' ambitions join other big longevity projects backed by billionaires. These projects include Altos Labs, founded by Jeff Bezos with a $3 billion investment, and Unity Biotechnology, which is backed by Bezos and Peter Thiel. This shows that the field of extending human life is attracting more and more attention from the technology and investment circles.

Retro Biosciences not only received capital support, but also integrated AI technology into drug research and development. Leveraging OpenAI’s powerful models, the company is trying to tackle some of the most challenging problems in life sciences. The technology of converting ordinary cells into stem cells offers new hope for the future of regenerative medicine.

Altman's redoubled investment in Retro Biosciences also reflects his recognition of the huge potential in the biotechnology field. He is not only a leader in the field of AI, but is also setting his sights on a broader field of technological innovation. With the continuous influx of capital and technology, extending human lifespan may no longer be just a distant dream.